Biotechnology

Genenta Science S.P.A.

Genenta Science S.P.A. released FY2025 Q2 earnings on October 10 EST, with actual revenue of USD 0 and EPS of USD -0.1193

Genenta Science S.P.A. released FY2025 Semi-Annual earnings on October 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.2296 (forecast USD -0.4213)

Genenta Science S.P.A. released FY2025 Q1 earnings on October 10 (EST), actual revenue USD 0, actual EPS USD -0.1103

Genenta Science S.P.A. released FY2024 9 Months Earnings on March 28 (EST), with actual revenue of 0 USD and EPS of -0.3866 USD

Genenta Science S.P.A. released FY2024 Q3 earnings on March 28 (EST), actual revenue 0 USD, actual EPS -0.1487 USD

Genenta Science S.P.A. released FY2024 Q4 earnings on March 28 (EST), actual revenue 0 USD, actual EPS -0.1385 USD

Genenta Science S.P.A. released FY2024 annual earnings on March 28 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.5247 USD (forecast -0.7017 USD)

Genenta Science S.P.A. released FY2024 Semi-Annual Earnings on October 29 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.2378 USD (forecast -0.3984 USD)

Genenta Science S.P.A. released FY2024 Q2 earnings on October 29 (EST) with actual revenue of 0 USD and EPS of -0.1184 USD

Genenta Science S.P.A. released FY2024 Q1 earnings on October 29, 2024 (EST), with actual revenue of 0 USD and EPS of -0.1193 USD

Genenta Science S.P.A. released FY2021 Q3 earnings on May 2, 2022 (EST), with actual revenue of 0 and EPS of -0.0558

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap